Table 2. Follow-up and medication analysis for echinococcosis patients treated with albendazole in ten endemic counties, 2019.
| Follow-up | Total (N) | Medication (N, %, 95% CI) | χ 2 | P* | |||||
| Rm=0 | 0<Rm<0.3 | 0.3≤Rm<0.5 | 0.5≤Rm<0.8 | Rm≥0.8 | Unrecorded | ||||
| Note: N represents the total number of patients. "Unrecorded" indicates a lack of medication records with corresponding follow-up data. Chi-square tests were utilized to determine the significance levels across varying ratio distributions. Abbreviation: CI=confidence interval; Rf=the ratio of actual to theoretical follow-up occurrences; Rm=the ratio of the actual duration of albendazole therapy to the recommended duration of therapy. * P-values were compared at the 0.05 significance level. | |||||||||
| Rf<0.3 | 69 | 8 (12.50, 4.17–20.83) | 27 (42.19, 29.75–54.62) | 23 (35.94, 23.86–48.02) | 6 (9.38, 2.04–16.71) | 0 | 5 | 281.745 | <0.001 |
| 0.3≤Rf<0.5 | 223 | 15 (8.29, 4.23–12.34) | 35 (19.34, 13.53–25.15) | 63 (34.81, 27.80–41.81) | 60 (33.15, 26.23–40.07) | 8 (4.42, 1.40–7.44) | 42 | ||
| 0.5≤Rf<0.8 | 162 | 21 (13.13, 7.84–18.41) | 15 (9.38, 4.81–13.94) | 42 (26.25, 19.36–33.14) | 53 (33.13, 25.75–40.50) | 29 (18.13, 12.09–24.16) | 2 | ||
| Rf≥0.8 | 139 | 0 | 0 | 2 (1.45, 0.57–3.47) | 45 (32.61, 24.69–40.53) | 91 (65.94, 57.94–73.95) | 1 | ||
| Total | 593 | 44 (8.10, 5.80–10.41) | 77 (14.18, 11.24–17.12) | 130 (23.94, 20.34–27.54) | 164 (30.20, 26.33–34.08) | 128 (23.57, 19.99–27.15) | 50 | ||